About Dr Adam Stirling
Is this you? - Claim your profileDr Adam Stirling is an experienced medical oncologist at Icon Cancer Centre Chermside, Wesley and North Lakes. In 2003 he attained his Bachelor of Medicine, Bachelor of Surgery (MBBS) with Honours at ...
Special interests
Awards and Publications
-
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. de Bono, J. S., Mehra, N., Scagliotti, G. V., Castro, E., Dorff, T., Stirling, A., Stenzl, A., Fleming, M. T., Higano, C. S., Saad, F., Buttigliero, C., van Oort, I. M., Laird, A. D., Mata, M., Chen, H. C., Healy, C. G., Czibere, A., & Fizazi, K. The Lancet. Oncology, 2021; 22(9), 1250–1264.
-
Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1. F. Saad, J.de Bono, P. Barthélémy, T. Dorff, N. Mehra, G. Scagliotti, A. Stirling, J. Machiels, V. Renard, M. Maruzzo, C. Higano, H. Gurney, C. Healy, H. Bhattacharyya, B. Arondekar, A. Niyazov & K. Fizazi. European Urology, 2022.
-
Abstract CT031: TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)– Exploration of genomic loss of heterozygosity (gLOH) and potential associations with antitumor activity. J. de Bono, N. Mehra, D. Laird, E. Castro, P. Barthelemy, R. Delva, G. Scagliotti, M. Maruzzo, A. Stirling, J. Machiels, H. Dumez, V. Renard, J. Hopkins, L. Albacker, H. Chen, C. Healy, J. Chelliserry, T. Dorff & K. Fizazi. Cancer Res, 2022; 82(12).
-
TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)—Exploration of germline DDR alteration landscape and potential associations with antitumor activity. T. Dorff, K. Fizazi, D. Laird, P. Barthelemy, R. Delva, M. Maruzzo, A. Stirling, J. Machiels, H. Dumez, V. Renard, J. Hopkins, H. Chen, C. Healy, J. Chelliserry, I. van Oort, G. Scagliotti, J.de Bono, N. Mehra. Journal of Clinical Oncology, 2022; 40(6), 157.
-
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. J.de Bono, N. Mehra, G. Scagliotti, E. Castro, T. Dorff, A. Stirling, A. Stenzl, M. Fleming, C. Higano, F. Saad & C. Buttiglier. The Lancet Oncology, 2021; 22(9), 1250-1264.
